Vanguard Group Inc Acelrx Pharmaceuticals Inc Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.35 $166,399 - $291,199	831,999 Added 22.26%	4,569,553 $955,000
Q2 2022 Aug 12, 2022	BUY	$0.18 - $0.29 $48,349 - $77,896	268,610 Added 7.74%	3,737,554 $913,000
Q1 2022 May 13, 2022	SELL	$0.28 - $0.61 $455,267 - $991,832	-1,625,955 Reduced 31.91%	3,468,944 $990,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $12,634 - $26,300	-25,785 Reduced 0.5%	5,094,899 $2.85 Million
Q3 2021 Nov 12, 2021	BUY	$0.93 - $1.51 $9,385 - $15,238	10,092 Added 0.2%	5,120,684 $5.22 Million
Q2 2021 Aug 13, 2021	BUY	$1.03 - $1.7 $5.26 Million - $8.69 Million	5,110,592 New	5,110,592 $7.05 Million

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.